Hypothesis

Transient pulses of OSK trigger a reversible loss of H3K9me3 at specific enhancer regions, creating an epigenetic memory that sustains a youthful state after factor withdrawal. The durability of this memory varies by tissue depending on the baseline level of H3K9 methyltransferases (e.g., SETDB1) and demethylases (e.g., KDM4D).

Mechanistic Basis

• OSK binding recruits TET enzymes and HDACs, leading to localized DNA demethylation and histone acetylation.
• Concurrently, OSK‑induced expression of KDM4D demethylates H3K9me3 at poised enhancers, preserving enhancer methylation patterns that prevent identity loss (see 5).
• In tissues with high SETDB1 activity, H3K9me3 is rapidly restored after OSK withdrawal, limiting memory; in low‑SETDB1 tissues (e.g., muscle, intestine) the demethylated state persists, extending rejuvenation.
• This model explains why short OSK pulses early in life produce lifelong benefits (4) while chronic expression erases identity.

Predictions

1. Measuring H3K9me3 levels at OSK‑responsive enhancers before and after a defined OSK pulse will predict the magnitude and duration of epigenetic age reversal in a given tissue.
2. Pharmacological inhibition of SETDB1 during OSK pulse will prolong the rejuvenated state in tissues that normally show transient effects (e.g., pancreas).
3. Overexpression of KDM4D will mimic the effect of a longer OSK pulse, extending lifespan without increasing tumor incidence.
4. Tissue‑specific rescue of SETDB1 after OSK withdrawal will erase the memory and accelerate epigenetic aging.

Experimental Design

• Use aged mice with a Cre‑inducible OSK cassette and a tissue‑specific Cre driver (e.g., MbCre for muscle, Pdx1Cre for pancreas).
• Deliver a single 48‑hour OSK pulse via doxycycline.
• At 0, 7, 30, and 90 days post‑pulse, perform CUT&Tag for H3K9me3 and ATAC‑seq on isolated cells.
• Correlate changes with epigenetic clock readings (e.g., Horvath mouse clock).
• Parallel cohorts receive SETDB1 inhibitor (e.g., chaetocin) or KDM4D overexpression via AAV.
• Assess functional outcomes (grip strength, glucose tolerance) and monitor for tumorigenicity.

Potential Confounds

• Off‑target doxycycline effects; include doxycycline‑only controls.
• Variability in Cre efficiency; validate with reporter lines.
• Compensatory histone modifications; examine H3K27ac and H3K4me1.

If the data show that H3K9me3 dynamics at OSK‑targeted enhancers dictate the longevity of rejuvenation, the hypothesis is supported. Conversely, uniform H3K9me3 changes across tissues with divergent functional outcomes would falsify the model.